Another Breakthrough! BioAlly’s Recombinant Feline Omega-Interferon Has Been Approved as a National Class II New Veterinary Drug!
Another Breakthrough! BioAlly’s Recombinant Feline Omega-Interferon Has Been Approved as a National Class II New Veterinary Drug!
2025-10-15
概要： On September 16, 2025, the Ministry of Agriculture and Rural Affairs issued Announcement No. 949: Recombinant feline interferon-α, independently developed by Taizhou BioAlly Biotechnology Co., Ltd., has been successfully approved for registration as a Class II new veterinary drug at the national level. This marks China’s first—and the world’s second—approved recombinant feline interferon, as well as the world’s first interferon product with dual applications: both injectable and ophthalmic. This milestone breakthrough not only signifies that China’s research and development in pet genetic engineering pharmaceuticals has entered the ranks of international leaders, but also fully demonstrates BioAlly’s outstanding capacity for technological innovation. Committed to independent R&D.
Another Breakthrough! BioAlly’s Recombinant Feline Omega-Interferon Has Been Approved as a National Class II New Veterinary Drug!
Building National Brands
Other News